Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

lesinurad Oral Tablet [Zurampic]

National Institutes of Health

Related topics

Related topics

3 relations
Oral TabletZurampic

Broader (1)

Zurampic Pill

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Lesinurad in hyperuricaemia of gout: a profile of its use in the EU
Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA production. The selective UA reabsorption… Expand
Review
2017
Review
2017
Lesinurad: A Review in Hyperuricaemia of Gout
  • E. Deeks
  • Drugs & Aging
  • 2017
    • Corpus ID: 3891146
Lesinurad (Zurampic®) is an oral selective inhibitor of the URAT1 and OAT4 uric acid (UA) transporters of the kidney, via which… Expand
  • table 1
  • figure 1
2017
2017
Case History: Zurampic® (Lesinurad): A Selective Uric Acid Reabsorption Inhibitor for the Treatment of Hyperuricemia in Gout Patients
2016
2016
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
BackgroundExcess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Review
2016
Review
2016
Lesinurad: First Global Approval
Lesinurad (ZURAMPIC®) is an oral urate–anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a… Expand
2016
2016
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
BACKGROUND Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE